Ficlatuzumab is Aveo’s novel HGF inhibitory antibody that is currently in phase II clinical development to treat non-small cell lung cancer (NSCLC).
Under the terms of the contract, Boehringer will produce ficlatuzumab for clinical trials at its site in Fremont, US, while Aveo retains the rights to develop and market ficlatuzumab.
Aveo executive vice president and chief business officer Elan Ezickson said Boehringer would make a suitable manufacturing partner owing to its expertise in monoclonal antibodies.
"This agreement is further evidence of the progress we are making in the clinical development of ficlatuzumab, and we look forward to working with Boehringer Ingelheim to prepare for the manufacturing activities for ficlatuzumab that would support phase III and beyond," Ezickson added.
Financial terms of the deal have not been revealed.